A different header for Outcomes

MolecuLight imaging provided real-time guidance for debridement and antibiotic selection in chronic lower extremity wounds. Removal of bacterial fluorescence signals was associated with reduced wound areas.

A “before and after” cohort study showing that fluorescence imaging reduced antibiotic and antimicrobial dressing needs and wound care costs while improving foot ulcer healing rates (39% to 48%).

RCT evidence that MolecuLight imaging dramatically improved DFU healing outcomes. Wound healing rates doubled at 12-weeks (45% vs. 22%) and the presence/absence of bacterial fluorescence reliably predicted the degree of wound closure.

A retrospective review across 55 long-term care facilities showing that MolecuLight significantly improved pressure injury outcomes compared to standard care alone. Patients treated with MolecuLight experienced a 71% higher healing rate, healed 28% faster, were 1.4 to 1.8 times more likely to heal, and experienced 75% fewer complications.

MolecuLight imaging prevented the need for intravenous antibiotics and hospitalization in 100% of wound-related cellulitis cases by aiding in early diagnosis and bacterial source control.

Fluorescence imaging predicted wound area reduction based on bacterial presence, with persistent bacterial loads correlating to worse outcomes. MolecuLight digital wound measurements were significantly more accurate than manual measurements (23% overestimation with ruler).